PerkinElmer’s Expansion into Tuberculosis Diagnostics
In a bold move, PerkinElmer has acquired Oxford Immunotec, a leading provider of tuberculosis (TB) diagnostics, for an impressive $591 million. This strategic acquisition positions PerkinElmer as a formidable competitor in the infectious disease market, particularly against Qiagen.
The T-SPOT.TB Test: A Game-Changer in TB Detection
Oxford Immunotec‘s flagship product, the T-SPOT.TB test, is a revolutionary diagnostic tool that measures T cells against Mycobacterium tuberculosis antigens. This cutting-edge technology allows for the detection of both active and latent TB infections, offering a significant advantage over traditional methods.
With remarkable performance, the T-SPOT.TB test boasts 95% sensitivity and 99% specificity, making it the most sensitive TB test available on the market. Its ability to deliver results within one to two days, eliminating the need for follow-up visits, further enhances its appeal.
Oxford Immunotec’s Impact on the TB Market
Oxford Immunotec‘s entry into the TB blood test market has significantly disrupted the landscape. Their T-SPOT.TB test has proven to be a formidable competitor to Qiagen’s QuantiFERON-TB Gold in-Tube test, with studies suggesting superior sensitivity and cost-effectiveness.
The global quantified TB testing market is estimated at a staggering $1 billion, and Oxford Immunotec has only begun to tap into this vast opportunity. With its innovative technology and proven track record, the company is poised for continued growth in this lucrative market.
PerkinElmer’s Grand Ambitions in Immunodiagnostics
Impact of Immunotec in the diagnosis of tuberculosis
- T-SPOT.TB test: Revolutionary detection of TB
- Disruption of the TB blood test market
- TB testing market estimated at $1 billion
- PerkinElmer Immunodiagnostic Expansion
- The future of infectious disease diagnosis
PerkinElmer’s acquisition of Oxford Immunotec is a testament to its ambitious plans in the immunodiagnostics space. The company has been aggressively expanding its portfolio, acquiring Euroimmun and Tulip in 2017, and now adding Oxford Immunotec to its arsenal.
With its existing diagnostics franchise experiencing impressive growth, driven by COVID-19-related sales, PerkinElmer sees Oxford Immunotec as a key asset in its long-term strategy. The acquired assets are expected to outperform the broader diagnostics franchise in the foreseeable future.
The Future of Infectious Disease Diagnostics
The acquisition of Oxford Immunotec by PerkinElmer marks a significant milestone in the evolution of infectious disease diagnostics. The T-SPOT.TB test has the potential to revolutionize TB detection and management, offering faster, more accurate, and more convenient testing options.
As the world continues to grapple with infectious diseases, the need for innovative and effective diagnostic tools is paramount. PerkinElmer’s acquisition of Oxford Immunotec is a bold step towards meeting this need, promising to shape the future of infectious disease diagnostics.
